Application 206843

Type: NDA
Sponsor: BRISTOL-MYERS SQUIBB

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	TABLET;ORAL	EQ 30MG BASE	Yes	No
002	DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	TABLET;ORAL	EQ 60MG BASE	Yes	No
003	DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	TABLET;ORAL	EQ 90MG BASE	Yes	No

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N206843-001	DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24
N206843-002	DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24
N206843-003	DAKLINZA	DACLATASVIR DIHYDROCHLORIDE	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13

Orange Book patents#

Current patent rows page 1 of 1 · 18 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N206843-001	8900566	2027-08-08	U-1724		2015-08-21
N206843-001	8900566	2027-08-08	U-1725		2015-08-21
N206843-001	9421192	2027-08-08	U-1724	Drug substance	2016-09-21
N206843-001	9421192	2027-08-08	U-1725	Drug substance	2016-09-21
N206843-001	8642025	2027-08-11	U-1724	Drug substance, Drug product	2015-08-21
N206843-001	8642025	2027-08-11	U-1725	Drug substance, Drug product	2015-08-21
N206843-001	8329159	2029-07-24		Drug substance	2015-08-21
N206843-001	8629171	2031-06-13	U-1724	Drug substance, Drug product	2015-08-21
N206843-002	8900566	2027-08-08	U-1724		2015-08-21
N206843-002	8900566	2027-08-08	U-1725		2015-08-21
N206843-002	9421192	2027-08-08	U-1724	Drug substance	2016-09-21
N206843-002	9421192	2027-08-08	U-1725	Drug substance	2016-09-21
N206843-002	8642025	2027-08-11	U-1724	Drug substance, Drug product	2015-08-21
N206843-002	8642025	2027-08-11	U-1725	Drug substance, Drug product	2015-08-21
N206843-002	8329159	2029-07-24		Drug substance	2015-08-21
N206843-002	8629171	2031-06-13	U-1724	Drug substance, Drug product	2015-08-21
N206843-003	9421192	2027-08-08	U-1724	Drug substance	2016-09-21
N206843-003	9421192	2027-08-08	U-1725	Drug substance	2016-09-21

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 123 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N206843-002	DAKLINZA	EQ 60MG BASE	TABLET / ORAL	RLD	2015-07-24	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N206843-003	DAKLINZA	EQ 90MG BASE	TABLET / ORAL	RLD	2016-04-13	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N206843-001	DAKLINZA	EQ 30MG BASE	TABLET / ORAL	RLD	2015-07-24	`8072bd15b7f6…`

Observed Orange Book patent history#

Patent history page 1 of 19 · 738 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N206843-001	8900566	2027-08-08	U-1725		2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	8900566	2027-08-08	U-1724		2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	8642025	2027-08-11	U-1724	Drug substance, Drug product	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	8642025	2027-08-11	U-1725	Drug substance, Drug product	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	8329159	2029-07-24		Drug substance	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-001	8629171	2031-06-13	U-1724	Drug substance, Drug product	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	8900566	2027-08-08	U-1725		2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	8900566	2027-08-08	U-1724		2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	8642025	2027-08-11	U-1724	Drug substance, Drug product	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	8642025	2027-08-11	U-1725	Drug substance, Drug product	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	8329159	2029-07-24		Drug substance	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-002	8629171	2031-06-13	U-1724	Drug substance, Drug product	2015-08-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-003	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N206843-003	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	8900566	2027-08-08	U-1725		2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	8900566	2027-08-08	U-1724		2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	8642025	2027-08-11	U-1724	Drug substance, Drug product	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	8642025	2027-08-11	U-1725	Drug substance, Drug product	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	8329159	2029-07-24		Drug substance	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-001	8629171	2031-06-13	U-1724	Drug substance, Drug product	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	8900566	2027-08-08	U-1725		2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	8900566	2027-08-08	U-1724		2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	8642025	2027-08-11	U-1724	Drug substance, Drug product	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	8642025	2027-08-11	U-1725	Drug substance, Drug product	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	8329159	2029-07-24		Drug substance	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-002	8629171	2031-06-13	U-1724	Drug substance, Drug product	2015-08-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-003	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N206843-003	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N206843-001	8900566	2027-08-08	U-1725		2015-08-21	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N206843-001	8900566	2027-08-08	U-1724		2015-08-21	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N206843-001	9421192	2027-08-08	U-1725	Drug substance	2016-09-21	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N206843-001	9421192	2027-08-08	U-1724	Drug substance	2016-09-21	`6a471c1ec25d…`

Observed Orange Book exclusivity history#

Exclusivity history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2019-12-13 00:20 UTC	2019-12	N206843-001	D-161	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-001	D-162	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-001	I-726	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-001	I-727	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-001	NCE	2020-07-24	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-002	D-161	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-002	D-162	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-002	I-726	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-002	I-727	2019-02-05	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N206843-002	NCE	2020-07-24	`74a2ff9319b5…`
2020-12-22 03:56 UTC	2020-12	N206843-001	NCE	2020-07-24	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N206843-002	NCE	2020-07-24	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N206843-001	NCE	2020-07-24	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N206843-002	NCE	2020-07-24	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N206843-001	D-161	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-001	D-162	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-001	I-726	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-001	I-727	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-001	NCE	2020-07-24	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-002	D-161	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-002	D-162	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-002	I-726	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-002	I-727	2019-02-05	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N206843-002	NCE	2020-07-24	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N206843-001	D-161	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-001	D-162	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-001	I-726	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-001	I-727	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-001	NCE	2020-07-24	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-002	D-161	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-002	D-162	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-002	I-726	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-002	I-727	2019-02-05	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N206843-002	NCE	2020-07-24	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N206843-001	D-161	2019-02-05	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N206843-001	D-162	2019-02-05	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N206843-001	I-726	2019-02-05	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N206843-001	I-727	2019-02-05	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N206843-001	NCE	2020-07-24	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N206843-002	D-161	2019-02-05	`ea99ee380514…`

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 8 matching rows.

NDC, Name, Nonproprietary name table
NDC	Name	Nonproprietary name	Labeler	Marketing category	Status
0003-0011	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0011	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0213	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0213	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0213	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0215	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0215	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current
0003-0215	DAKLINZA	daclatasvir	E.R. Squibb & Sons, L.L.C.	NDA	Current

Documents#

Document, Submission type, Date table
Document	Submission type	Date
60580	SUPPL	2019-10-17
60574	SUPPL	2019-10-17
50400	SUPPL	2017-11-14
50381	SUPPL	2017-11-13
47250	SUPPL	2017-02-16
47221	SUPPL	2017-02-15
45165	SUPPL	2016-08-24
45164	SUPPL	2016-08-24
19739	SUPPL	2016-04-14
44952	SUPPL	2016-03-03
44951	SUPPL	2016-03-03
40569	SUPPL	2016-02-25
40568	SUPPL	2016-02-25
19738	SUPPL	2016-02-25
32830	SUPPL	2016-02-09
10601	SUPPL	2016-02-09
10600	SUPPL	2016-02-09
23027	ORIG	2015-08-28
19737	ORIG	2015-07-30
10599	ORIG	2015-07-28